A news article about a pharmaceutical collaboration that explains the nature of a license-and-development partnership to advance next-generation ADCs and what readers can expect to learn.
Key Takeaways
- DualityBio will lead discovery and early global clinical development for ADCs using its DUPAC payloads
- Genentech obtains exclusive worldwide licenses and will handle development and commercialization after Phase 1a
- DualityBio will receive $45 million upfront, over $1 billion in potential milestones, and tiered royalties